Breaking News

Savillex Acquires ONFAB

Containment solutions provider expands Savillex's ability to serve global pharmaceutical, biopharmaceutical, and CMOs.

Savillex, a provider of high-performance rigid plastic containers, has completed its acquisition of UK-based flexible containment solution provider ONFAB. 

ONFAB expands Savillex’s ability to serve global pharmaceutical, biopharmaceutical, and contract manufacturing organizations with innovative containment solutions. ONFAB focuses on designing and fabricating innovative flexible isolator systems.

The designs are custom-made to the unique needs of each customer’s pharmaceutical manufacturing process and protect users from highly potent pharmaceutical ingredients. ONFAB’s systems are designed to reduce manufacturing costs, minimize cleaning and cleaning validation times, and shorten downtime for equipment changeout.

The acquisition combines a strong flexible containment equipment portfolio with Savillex’s expertise in rigid containers, custom container projects, and closed mixing systems specifically designed for life sciences.

As part of Savillex, ONFAB customers and channel partners will have access to a full suite of specialized rigid container solutions for their projects. The Savillex brand gains an international footprint with increased ability to serve global customers.

“We are very excited to add ONFAB into the Savillex family.” said Steve Harding, President of Savillex. “The combination of Savillex and ONFAB enable us to offer a broader range of container and containment solutions to our customers by combining our complementary engineering and production capabilities and product portfolios.”

Mark Arnold, Managing Director at ONFAB said, “The ONFAB UK and Europe teams are thrilled to be joining the Savillex family in the USA to form a wider reaching platform, with an expanded product offering for all our global customers.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters